Aquablation has recently made its debut in Greece in 2025, spearheaded by the European Clinic Group, which is proud to introduce this revolutionary and innovative technique exclusively for patients. Benign prostatic hyperplasia (BPH) is the most common urological condition affecting men as they age, characterized by the enlargement of the prostate gland that can lead to various symptoms such as difficulty urinating, frequent urination, nocturia, and the sensation of incomplete bladder emptying. Many patients eventually require surgical intervention despite the common use of medication to manage BPH symptoms.

Aquablation represents a new and innovative minimally invasive surgical method that has garnered significant attention for the treatment of BPH. This technique combines robotic technology with water-based interventions, allowing for a precise and effective way to address the symptoms of BPH while minimizing recovery time and procedural risks. As awareness and access to Aquablation increase, more patients may benefit from this state-of-the-art treatment option for a condition that affects so many older men.

The introduction of Aquablation in Greece signals a promising advancement in the management of BPH, showcasing the commitment of healthcare institutions to adopt cutting-edge technologies that enhance patient care. As the European Clinic Group leads the way in integrating such innovative procedures, the future of prostate health management looks brighter, potentially improving the quality of life for countless men who suffer from this common urological issue.